Evaluating XOR Levels in Patients with Obstructive Sleep Apnea
Obstructive Sleep Apnea Severity and Xanthine Oxidoreductase Activity: Mechanisms and Clinical Implications
This study is testing how levels of a specific enzyme change in people with obstructive sleep apnea when they use CPAP treatment for three months.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06554496 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of xanthine oxidoreductase (XOR) levels in patients with Obstructive Sleep Apnea (OSA) and how these levels change with Continuous Positive Airway Pressure (CPAP) treatment. It will enroll 80 patients aged 18-80, categorized by the severity of their OSA based on the Apnea-Hypopnea Index (AHI). Participants will undergo baseline assessments including polysomnography and biomarker measurements, followed by a 3-month CPAP intervention. The study aims to clarify the relationship between XOR activity and OSA severity, as well as the impact of CPAP on XOR levels.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 years who are newly diagnosed with Obstructive Sleep Apnea and have not previously undergone CPAP treatment.
Not a fit: Patients with severe underlying conditions such as significant vascular diseases, severe COPD, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the oxidative stress mechanisms in OSA and improve treatment strategies through targeted CPAP therapy.
How similar studies have performed: While the specific role of XOR in OSA has not been extensively studied, related research on oxidative stress in sleep apnea has shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged between 18 and 80 years. 2. Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h). 3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA. 4. Ability and willingness to provide informed consent for participation in the study. Exclusion Criteria: 1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results. 2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases. 3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition. 4. Pregnancy or having other conditions that make participation in this study unsuitable. 5. Extremely debilitated patients or those with severe underlying conditions.
Where this trial is running
Nanjing, Jiangsu
- The First Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.